Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas
- PMID: 35875393
- PMCID: PMC9305371
- DOI: 10.1016/j.jdin.2022.06.001
Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas
Abstract
Background: Reliable evidence to guide the management of melanoma in situ (MIS) and minimize the risk of recurrence is lacking.
Objective: To identify clinicopathological predictors of local recurrence (LR) in patients with MIS and evaluate long-term outcomes according to pathological excision margins.
Methods: A case-control study of patients with MIS treated at a large Australian melanoma treatment center from January 2008 to December 2012 was undertaken. Clinicopathological characteristics of patients who developed LR and those who did not were compared.
Results: LR developed in 34 of 1407 patients with MIS (2.5%). Median time to LR was 20 months. The primary lesion was removed with pathological margins <4 mm (P < .001) in 67.6 % of patients with LR. Four patients died of metastatic melanoma following LR. Comparing patients with pathological margins <4 mm and ≥4 mm, the former were older (>60y, P < .001), more frequently had MIS on the head or neck (P < .001), had a greater LR rate (P < .001), and had a higher mortality from all causes (P < .001).
Limitations: Retrospective, single-institution study.
Conclusions: Pathological margins of ≥4 mm should be considered for patients with MIS who are treated with standard surgical excision and assessed by examining serial slices taken from the formalin-fixed, paraffin-embedded specimen.
Keywords: CCPDMA, complete circumferential peripheral and deep margin assessment; LM, lentigo maligna; LR, local recurrence; MIA, Melanoma Institute Australia; MIS, melanoma in situ; excision margins; in situ melanoma; local recurrence; melanoma; wider excision.
© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
Conflict of interest statement
RAS has received fees for professional services from Evaxion, Provectus Inc, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc, Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Inc and travel and conference support from GSK, Provectus Inc, and Novartis.
Similar articles
-
Surgical management of melanoma-in-situ using a staged marginal and central excision technique.Ann Surg Oncol. 2009 Jun;16(6):1526-36. doi: 10.1245/s10434-008-0239-x. Epub 2008 Dec 3. Ann Surg Oncol. 2009. PMID: 19050971
-
An assessment of histological margins and recurrence of melanoma in situ.Plast Reconstr Surg Glob Open. 2015 Mar 6;3(2):e301. doi: 10.1097/GOX.0000000000000272. eCollection 2015 Feb. Plast Reconstr Surg Glob Open. 2015. PMID: 25750840 Free PMC article.
-
Surgical excision margins for melanoma in situ.J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):320-3. doi: 10.1016/j.bjps.2013.11.014. Epub 2013 Dec 12. J Plast Reconstr Aesthet Surg. 2014. PMID: 24444795
-
Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.Adv Ther. 2021 Jul;38(7):3506-3530. doi: 10.1007/s12325-021-01783-x. Epub 2021 May 28. Adv Ther. 2021. PMID: 34047915 Free PMC article. Review.
-
Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.Int J Dermatol. 2010 May;49(5):482-91. doi: 10.1111/j.1365-4632.2010.04423.x. Int J Dermatol. 2010. PMID: 20534080 Review.
Cited by
-
The clinical practice and outcomes of minimally invasive surgery in primary malignant melanoma of the vagina and cervix patients: a retrospective cohort study.Orphanet J Rare Dis. 2025 Jun 6;20(1):286. doi: 10.1186/s13023-025-03760-x. Orphanet J Rare Dis. 2025. PMID: 40481497 Free PMC article.
-
Amoeba-Inspired Soft Robot for Integrated Tumor/Infection Therapy and Painless Postoperative Drainage.Adv Sci (Weinh). 2024 Dec;11(47):e2407148. doi: 10.1002/advs.202407148. Epub 2024 Nov 4. Adv Sci (Weinh). 2024. PMID: 39494576 Free PMC article.
References
-
- Fitzsimmons G.J., Sadkowsky K.R. The Australian Institute of Health and Welfare. Commun Dis Intell Q Rep. 2002;26:605–607. - PubMed
-
- Aitken J.F., Youlden D.R., Baade P.D., Soyer H.P., Green A.C., Smithers B.M. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer. 2018;142:1528–1535. - PubMed
-
- Robinson M., Primiero C., Guitera P., et al. Evidence-based clinical practice guidelines for the management of patients with lentigo maligna. Dermatology. 2020;236:111–116. - PubMed
LinkOut - more resources
Full Text Sources